| 摘要 |
The present invention relates to a novel tetranuclear arene ruthenium compound, and to a pharmaceutical composition for preventing or treating cancer, comprising the same as an active ingredient. The tetranuclear arene ruthenium compound exhibits anticancer activities in comparison with doxorubicin and cisplatin, publicly known anticancer drugs, and particularly exhibits excellent anticancer activities by strongly inducing autophagy at low concentrations in colon cancer cells, thereby being efficiently used for preventing or treating cancer. |
